|
1
|
Focosi D: Acute myeloid leukaemia. Lancet.
369:3672007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Waller CF: Imatinib mesylate. Recent
Results Cancer Res. 201:1–25. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Moreau P, Richardson PG, Cavo M, Orlowski
RZ, San Miguel JF, Palumbo A and Harousseau JL: Proteasome
inhibitors in multiple myeloma: 10 years later. Blood. 120:947–959.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kiper HD, Kaymaz B Tezcanli, Gokbulut AA,
Selvi N, Avci CB, Kosova B, Iskender G, Yandim MK, Gunduz C, Sahin
F, et al: STAT pathway in the regulation of zoledronic acid-induced
apoptosis in chronic myeloid leukemia cells. Biomed Pharmacother.
67:527–532. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jagdev SP, Coleman RE, Shipman CM, Rostami
HA and Croucher PI: The bisphosphonate, zoledronic acid, induces
apoptosis of breast cancer cells: Evidence for synergy with
paclitaxel. Br J Cancer. 84:1126–1134. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Stresing V, Fournier PG, Bellahcéné A,
Benzaïd I, Mönkkönen H, Colombel M, Ebetino FH, Castronovo V and
Clézardin P: Nitrogen-containing bisphosphonates can inhibit
angiogenesis in vivo without the involvement of farnesyl
pyrophosphate synthase. Bone. 48:259–266. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tassone P, Tagliaferri P, Viscomi C,
Palmieri C, Caraglia M, D'Alessandro A, Galea E, Goel A, Abbruzzese
A, Boland CR and Venuta S: Zoledronic acid induces
antiproliferative and apoptotic effects in human pancreatic cancer
cells in vitro. Br J Cancer. 88:1971–1978. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Goffinet M, Thoulouzan M, Pradines A,
Lajoie-Mazenc I, Weinbaum C, Faye JC and Séronie-Vivien S:
Zoledronic acid treatment impairs protein geranyl-geranylation for
biological effects in prostatic cells. BMC Cancer. 6:602006.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Iguchi T, Miyakawa Y, Yamamoto K, Kizaki M
and Ikeda Y: Nitrogen-containing bisphosphonates induce S-phase
cell cycle arrest and apoptosis of myeloma cells by activating MAPK
pathway and inhibiting mevalonate pathway. Cell Signal. 15:719–727.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Oades GM, Senaratne SG, Clarke IA, Kirby
RS and Colston KW: Nitrogen containing bisphosphonates induce
apoptosis and inhibit the mevalonate pathway, impairing Ras
membrane localization in prostate cancer cells. J Urol.
170:246–252. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kuroda J, Kimura S, Segawa H, Kobayashi Y,
Yoshikawa T, Urasaki Y, Ueda T, Enjo F, Tokuda H, Ottmann OG and
Maekawa T: The third-generation bisphosphonate Zoledronic Acid
synergistically augments the anti-Ph+ leukemia activity of imatinib
mesylate. Blood. 102:2229–2235. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fiegl M, Juergens M, Hiddemann W and
Braess J: Cytotoxic activity of the third-generation bisphosphonate
zoledronic acid in acute myeloid leukemia. Leuk Res. 31:531–539.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ohtsuka Y, Manabe A, Kawasaki H, Hasegawa
D, Zaike Y, Watanabe S, Tanizawa T, Nakahata T and Tsuji K:
RAS-blocking bisphosphonate zoledronic acid inhibits the abnormal
proliferation and differentiation of juvenile myelomonocytic
leukemia cells in vitro. Blood. 106:3134–3141. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chuah C, Barnes DJ, Kwok M, Corbin A,
Deininger MW, Druker BJ and Melo JV: Zoledronate inhibits
proliferation and induces apoptosis of imatinib-resistant chronic
myeloid leukaemia cells. Leukemia. 19:1896–1904. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ebihara Y, Tsuji K, Lyman SD, Sui X,
Yoshida M, Muraoka K, Yamada K, Tanaka R and Nakahata T:
Synergistic action of Flt3 and gp130 signalings in human
hematopoiesis. Blood. 90:4363–4368. 1997.PubMed/NCBI
|
|
16
|
Hatzimichael E, Georgiou G, Benetatos L
and Briasoulis E: Gene mutations and molecularly targeted therapies
in acute myeloid leukemia. Am J Blood Res. 3:29–51. 2013.PubMed/NCBI
|
|
17
|
Liu SS, Wang XP, Li XB, Liang JY, Liu LL,
Lu Y, Zhong XY and Chen YX: Zoledronic acid exerts antitumor
effects in NB4 acute promyelocytic leukemia cells by inducing
apoptosis and S phase arrest. Biomed Pharmacother. 68:1031–1036.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang L, Chen B, Lin M, Cao Y, Chen Y, Chen
X, Liu T and Hu J: Decreased expression of nucleophosmin/B23
increases drug sensitivity of adriamycin-resistant Molt-4 leukemia
cells through mdr-1 regulation and Akt/mTOR signaling.
Immunobiology. 220:331–340. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang B, Yang Y, Shi X, Liao W, Chen M,
Cheng AS, Yan H, Fang C, Zhang S, Xu G, et al: Proton pump
inhibitor pantoprazole abrogates adriamycin-resistant gastric
cancer cell invasiveness via suppression of Akt/GSK-β/β-catenin
signaling and epithelial-mesenchymal transition. Cancer Lett.
356:704–712. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Forsea AM, Müller C, Riebeling C, Orfanos
CE and Geilen CC: Nitrogen-containing bisphosphonates inhibit cell
cycle progression in human melanoma cells. Br J Cancer. 91:803–810.
2004.PubMed/NCBI
|
|
21
|
Wong WW and Puthalakath H: Bcl-2 family
proteins: The sentinels of the mitochondrial apoptosis pathway.
IUBMB Life. 60:390–397. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ottewell PD, Woodward JK, Lefley DV, Evans
CA, Coleman RE, Holen I and Penelope D: Anticancer mechanisms of
doxorubicin and zoledronic acid in breast cancer tumor growth in
bone. Mol Cancer Ther. 8:2821–2832. 2009. View Article : Google Scholar : PubMed/NCBI
|
